PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

Cell Reports

Volumn 12, Issue 12, 2015, Pages 1978-1985

  Prahallad, Anirudh ^a   Heynen, Guus J J E ^a   Germano, Giovanni ^b,c   Willems, Stefan M ^a,d   Evers, Bastiaan ^a   Vecchione, Loredana ^a   Gambino, Valentina ^a   Lieftink, Cor ^a   Beijersbergen, Roderick L ^a   Di Nicolantonio, Federica ^b,e   Bardelli, Alberto ^b,e   Bernards, Rene ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GS 493; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; VEMURAFENIB; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; INDOLE DERIVATIVE; PTPN11 PROTEIN, HUMAN; RAS PROTEIN; SMALL INTERFERING RNA; SULFONAMIDE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESISTANCE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE LIBRARY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HIGH THROUGHPUT SEQUENCING; LENTIVIRINAE; MELANOMA; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; GENOMIC LIBRARY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDOLES; LENTIVIRUS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, INBRED NOD; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SULFONAMIDES; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942833027     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.08.037     Document Type: Article

References (35)

1. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
2. Araki T., Nawa H., Neel B.G. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J. Biol. Chem. 2003, 278:41677-41684.
3. Bennett A.M., Hausdorff S.F., O'Reilly A.M., Freeman R.M., Neel B.G. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol. Cell. Biol. 1996, 16:1189-1202.
4. Bentires-Alj M., Paez J.G., David F.S., Keilhack H., Halmos B., Naoki K., Maris J.M., Richardson A., Bardelli A., Sugarbaker D.J., et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004, 64:8816-8820.
5. Bernards R. Finding effective cancer therapies through loss of function genetic screens. Curr. Opin. Genet. Dev. 2014, 24:23-29.
6. Chan G., Kalaitzidis D., Neel B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008, 27:179-192.
7. Chen L., Sung S.S., Yip M.L., Lawrence H.R., Ren Y., Guida W.C., Sebti S.M., Lawrence N.J., Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 2006, 70:562-570.
8. Choi J., Landrette S.F., Wang T., Evans P., Bacchiocchi A., Bjornson R., Cheng E., Stiegler A.L., Gathiaka S., Acevedo O., et al. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014, 27:253-262.
9. Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Della Pelle P., Dias-Santagata D., Hung K.E., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
10. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
11. Grosskopf S., Eckert C., Arkona C., Radetzki S., Böhm K., Heinemann U., Wolber G., von Kries J.P., Birchmeier W., Rademann J. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. ChemMedChem 2015, 10:815-826.
12. Hellmuth K., Grosskopf S., Lum C.T., Würtele M., Röder N., von Kries J.P., Rosario M., Rademann J., Birchmeier W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. USA 2008, 105:7275-7280.
13. Hendriks W.J., Elson A., Harroch S., Pulido R., Stoker A., den Hertog J. Protein tyrosine phosphatases in health and disease. FEBS J. 2013, 280:708-730.
14. Higashi H., Tsutsumi R., Muto S., Sugiyama T., Azuma T., Asaka M., Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Protein Sci. 2002, 295:683-686.
15. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
16. Loh M.L., Vattikuti S., Schubbert S., Reynolds M.G., Carlson E., Lieuw K.H., Cheng J.W., Lee C.M., Stokoe D., Bonifas J.M., et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004, 103:2325-2331.
17. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014, 371:1877-1888.
18. Mohi M.G., Williams I.R., Dearolf C.R., Chan G., Kutok J.L., Cohen S., Morgan K., Boulton C., Shigematsu H., Keilhack H., et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005, 7:179-191.
19. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
20. Ostman A., Hellberg C., Böhmer F.D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006, 6:307-320.
21. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
22. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
23. Qu C.K. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res. 2000, 10:279-288.
24. Sacco F., Gherardini P.F., Paoluzi S., Saez-Rodriguez J., Helmer-Citterich M., Ragnini-Wilson A., Castagnoli L., Cesareni G. Mapping the human phosphatome on growth pathways. Mol. Syst. Biol. 2012, 8:603.
25. Shi Z.Q., Yu D.H., Park M., Marshall M., Feng G.S. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol. Cell. Biol. 2000, 20:1526-1536.
26. Shirdel E.A., Xie W., Mak T.W., Jurisica I. NAViGaTing the micronome--using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PLoS ONE 2011, 6:e17429.
27. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
28. Sun C., Hobor S., Bertotti A., Zecchin D., Huang S., Galimi F., Cottino F., Prahallad A., Grernrum W., Tzani A., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014, 7:86-93.
29. Sun C., Wang L., Huang S., Heynen G.J., Prahallad A., Robert C., Haanen J., Blank C., Wesseling J., Willems S.M., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
30. Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., van der Burgt I., Crosby A.H., Ion A., Jeffery S., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 2001, 29:465-468.
31. Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J., Jung A., Hählen K., Hasle H., Licht J.D., Gelb B.D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 2003, 34:148-150.
32. Wagenaar T.R., Ma L., Roscoe B., Park S.M., Bolon D.N., Green M.R. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. Pigment Cell Melanoma Res. 2014, 27:124-133.
33. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
34. Zhan Y., Counelis G.J., O'Rourke D.M. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp. Cell Res. 2009, 315:2343-2357.
35. Zhao S., Sedwick D., Wang Z. Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 2015, 34:3885-3894.